clinical Evaluation of hydroalcoholic extract of Mangifera indica leaf in patients with coronavirus in Valiasr Hospital, Fasa, 2021

Evaluation the effect of flavonoid content of Mangifera indica leaf extract by prescribing capsules containing 500 mg of extract on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients hospitalized

A triple-blind clinical trial, two treatment groups and a parallel control group will be performed on 60 patients. For randomization, we will use the method of permutation blocks with a number of 6 blocks using Random allocation software.

Patients with COVID19 admitted to Vali-e-Asr Hospital in Fasa are divided into two groups A and B. The anti-inflammatory effects of mango leaf extract will be evaluated with 500 mg capsules. The study will be blinded at the level of outcome assessor, pathologist and statistical analyst of results. Location: Fasa University of Medical Sciences

Inclusion criteria: 1. Definitive diagnosis of COVID-19 2. Age between 18 to 65 years 3. Both sexes (male and female) 4. Having informed and written consent to participate in the study 5. No history of any allergies 6. No use Anticoagulants 7. Non-pregnancy and lactation 8. Absence of diabetes in the person Conditions for not entering the study: 1. Disagreement of the physician in charge of the patient 2. History of any allergies 3. History of heart and kidney disease 4. Patient dissatisfaction 5. History blood pressure

Divide patients into two similar groups A and B. The treatment group contained capsules containing 500 mg of plant leaf extract (Mangifera indica) and the placebo group contained 500 mg capsules containing popcorn flour. By introducing the plan and justifying the patient, written consent is received.

Duration of hospitalization

This study will be performed on patients with coronavirus hospitalized in Vali Asr Hospital in Fasa. the patients data will be record (medication regimen, age and sex, severity of disease and severity of symptoms) by individualize code. The relevant expert divides the patients into two similar groups based on the treatment regimen, age group, gender, severity and symptoms, of the disease, and randomly divides one group into group A and one group into group B using the patient. For randomization, the permutation block method with the number of blocks of 6 is done using Random allocation software.

after fulfillment of inclusion criteria the physician will be prescribe A (the drug) or B (placebo) according to the randomized sheet. the prescription will be dispense in the same package. healthcare givers will be unaware about coding dedicated to every patient. The results of the two groups under the headings of groups A and B will be delivered to the statistical analyzer.

Some of the information obtained will be available based on changes in initial outcomes.

Start of access period 6 months after production and publication of results

People engaged in research in medical universities of the country

The methods and data contained in this clinical trial should be used solely to advance similar projects. It is also necessary to mention the research center of this study (Fasa University of Medical Sciences) if information is used

Amin Dakhili Ardestani, Email Address: Amindakhiliardestani@yahoo.com Contact Number: 09228584505 Address: Fasa University, Ibn Sina Square, Fasa University of Medical Sciences and Health Services

1. Contacting the general respondent of the study 2. Sending his formal request to the respondent 3. The application form in the University Research Council 4. In case of a positive response from the council, it will be provided to the applicant in accordance with the ethical principles. 5. The total duration of the process is 20 days.